FAQs
Show All
What is Fulgent’s business?
Fulgent is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Please reference the company’s public filings with the Securities and Exchange Commission for additional information.
Please reference the company’s public filings with the Securities and Exchange Commission for additional information.
When was Fulgent founded and what is its history?
Fulgent was founded in 2011. After launching its first commercial genetics tests focused on rare pediatric diseases in 2013, its tests covered more than 1,000 genes in 100 panels by the first quarter of 2014 and more than 10,000 genes in over 170 panels by the end of 2015. Today, Fulgent has further expanded its test menu to offer more than 18,000 single-gene tests and more than 200 panels that collectively test for more than 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders.
Please reference the company’s public filings with the Securities and Exchange Commission for additional information.
Please reference the company’s public filings with the Securities and Exchange Commission for additional information.
When did Fulgent go public?
Fulgent’s common stock began trading on the NASDAQ Global Market on September 28, 2016.
Who were the underwriters in the IPO?
Credit Suisse and Piper Jaffray served as the bookrunners, Raymond James served as the co-lead manager, and BTIG served as the co-manager.
How can I obtain a copy of the final prospectus?
The prospectus can be accessed in the SEC Filings section of this website.
What is Fulgent’s symbol and where does the stock trade?
Fulgent’s ticker symbol is FLGT and its common stock is listed for trading on the Nasdaq Global Market.
How can I find historical prices for Fulgent’s common stock?
Historical stock price information can be accessed in the Stock Information section of this website.
Who is Fulgent’s transfer agent?
Fulgent’s transfer agent and registrar for its common stock is Computershare Trust Company, N.A., whose address is 250 Royall Street, Canton, Massachusetts 02021.
What is Fulgent’s CUSIP number?
The CUSIP number for Fulgent’s common stock is 359664 109.
When does Fulgent’s fiscal year end?
Fulgent’s fiscal year-end is December 31.
How can I contact Investor Relations for Fulgent?
Please submit any questions on our information request form.